# VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium

> **NCT00407485** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 22 (actual)

## Conditions studied

- Adenocarcinoma of the Bladder
- Distal Urethral Cancer
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
- Proximal Urethral Cancer
- Recurrent Bladder Cancer
- Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
- Recurrent Urethral Cancer
- Squamous Cell Carcinoma of the Bladder
- Stage III Bladder Cancer
- Stage III Urethral Cancer
- Stage IV Bladder Cancer
- Transitional Cell Carcinoma of the Bladder
- Urethral Cancer Associated With Invasive Bladder Cancer

## Interventions

- **BIOLOGICAL:** ziv-aflibercept
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00407485
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2010-04
- **Final completion:** 2014-04
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2014-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00407485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00407485, "VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00407485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*